Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck® HPV-screening assay

Journal of Clinical Virology

Volumn 47, Issue 1, 2010, Pages 38-42

  Halfon, Philippe ^a,b   Benmoura, Dominique ^a   Khiri, Hacene ^b   Penaranda, Guillaume ^c   Blanc, Bernard ^a   Riggio, Daniela ^d   Sandri, Maria Teresa ^d  

^a Hospital Ambroise Pare   (France)

^b Laboratoire Alphabio   (France)

^c CDL Pharma   (France)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Genotypes; HPV; Hybrid Capture II; Linear Array; Papillocheck

Indexed keywords

ADULT; AGED; ARTICLE; ASSAY; COLPOSCOPY; CONTROLLED STUDY; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRIORITY JOURNAL; SCREENING; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; VIRUS TYPING; WART VIRUS;

ADOLESCENT; ADULT; AGED; ALPHAPAPILLOMAVIRUS; BIOPSY; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CHI-SQUARE DISTRIBUTION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 72049124556     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.10.013     Document Type: Article

References (27)

1. Bulkmans N.W., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370 (2007) 1764-1772
2. Munoz N., Castellsague X., de Gonzalez A.B., and Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 24 Suppl. 3 (2006) S3 1-10
3. Arbyn M., Ronco G., Cuzick J., Wentzensen N., and Castle P.E. How to evaluate emerging technologies in cervical cancer screening?. Int J Cancer (2009)
4. Szarewski A., Ambroisine L., Cadman L., Austin J., Ho L., Terry G., et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 17 (2008) 3033-3042
5. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121 (2007) 621-632
6. Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357 (2007) 1579-1588
7. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 101 (2009) 88-99
8. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124 (2009) 516-520
9. Snijders P.J., van den Brule A.J., and Meijer C.J. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 201 (2003) 1-6
10. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
11. Meijer C.J., Snijders P.J., and Castle P.E. Clinical utility of HPV genotyping. Gynecol Oncol 103 (2006) 12-17
12. Woodman C.B., Collins S.I., and Young L.S. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7 (2007) 11-22
13. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2 (2002) 342-350
14. Wright Jr. T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 197 (2007) 346-355
15. Huang Y.K., You S.L., Yuan C.C., Ke Y.M., Cao J.M., Liao C.Y., et al. Long-term outcomes of high-risk human papillomavirus infection support a long interval of cervical cancer screening. Br J Cancer 98 (2008) 863-869
16. Huang S., Tang N., Mak W., Erickson B., Salituro J., and Li Y. Principles and analytical performance of Abbott RealTime High Risk HPV test. J Clin Virol 45 (2009) S13-S17
17. Monsonego J., Pollini G., Evrard M.J., Sednaoui P., Monfort L., Zerat L., et al. Detection of human papillomavirus genotypes among high-risk women: a comparison of hybrid capture and linear array tests. Sex Transm Dis 35 (2008) 521-527
18. Dalstein V., Merlin S., Bali C., Saunier M., Dachez R., and Ronsin C. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J Virol Methods 156 (2009) 77-83
19. Wentzensen N., Schiffman M., Dunn S.T., Zuna R.E., Walker J., Allen R.A., et al. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer 124 (2009) 964-969
20. Terry G., Ho L., Londesborough P., Cuzick J., Mielzynska-Lohnas I., and Lorincz A. Detection of high-risk HPV types by the hybrid capture 2 test. J Med Virol 65 (2001) 155-162
21. Hesselink A.T., Bulkmans N.W., Berkhof J., Lorincz A.T., Meijer C.J., and Snijders P.J. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol 44 (2006) 3680-3685
22. Safaeian M., Herrero R., Hildesheim A., Quint W., Freer E., Van Doorn L.J., et al. Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J Clin Microbiol 45 (2007) 1447-1454
23. Sandri M.T., Lentati P., Benini E., Dell'Orto P., Zorzino L., Carozzi F.M., et al. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol 44 (2006) 2141-2146
24. Stevens M.P., Garland S.M., and Tabrizi S.N. Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J Virol Methods 147 (2008) 290-296
25. Monsonego J., Bohbot J.M., Pollini G., Krawec C., Vincent C., Merignargues I., et al. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol Oncol 99 (2005) 160-168
26. Pretet J.L., Jacquard A.C., Carcopino X., Charlot J.F., Bouhour D., Kantelip B., et al. Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. Int J Cancer 122 (2008) 428-432
27. Pretet J.L., Jacquard A.C., Saunier M., Clavel C., Dachez R., Gondry J., et al. Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer: the EDiTH III study. Gynecol Oncol 110 (2008) 179-184